Article
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Antimicrobial agents and chemotherapy - 1 Feb 2013
Fenaux Martijn, Eng Stacey, Leavitt Stephanie A, Lee Yu-Jen, Mabery Eric M, Tian Yang, Byun Daniel, Canales Eda, Clarke Michael O, Doerffler Edward, Lazerwith Scott E, Lew Willard, Liu Qi, Mertzman Michael, Morganelli Philip, Xu Lianhong, Ye Hong, Zhang Jennifer, Matles Mike, Murray Bernard P, Mwangi Judy, Zhang Jingyu, Hashash Ahmad, Krawczyk Steve H, Bidgood Alison M, Appleby Todd C, Watkins William J
Abstract excerpt
GS-9669 is a highly optimized thumb site II nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, with a binding affinity of 1.35 nM for the genotype (GT) 1b protein. It is a selective inhibitor of HCV RNA replication, with a mean 50% effective concentration (EC(50)) of ≤ 11 nM in genotype 1 and 5 replicon assays, but lacks useful activity against genotypes 2 to 4. The M423T mutation is readily...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
